| Date | Time | Source | |
| 04/25/2024 | 9:09AM | IHMARKETNEWS | Futures Pointing To Sharply Lower Open On Wall Street
The major U.S. index futures are currently pointing to a sharply lower open on Thursday, with stocks likely to come under pressure following the lackluster performance seen in the previous session. A negative reaction to earnings news from Meta Platforms (NASDAQ:META) is likely to weigh on Wall Street, as the Facebook... More...>> |
| 04/25/2024 | 7:52AM | IHMARKETNEWS | Southwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on Earnings
Southwest Airlines (NYSE:LUV) – Southwest Airlines’ shares fell 9.6% in pre-market trading after reporting a larger first-quarter loss compared to the previous year and warned of potential delays from Boeing impacting its growth until 2025. The company plans to increase capacity by 4%, below the planned 6... More...>> |
| 04/25/2024 | 6:30AM | BW | Merck Announces First-Quarter 2024 Financial Results
Sales Reflect Continued Strong Growth in Oncology and Vaccines Total Worldwide Sales Were $15.8 Billion, an Increase of 9% From First Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 12% KEYTRUDA Sales Grew 20% to $6.9 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 24% GARDASIL/GARDASIL... More...>> |
| 04/19/2024 | 7:04AM | PRNCA | Santé Canada approuve KEYTRUDA® comme traitement de première intention, en association avec une chimiothérapie à base de fluoropyrimidine et de platine, des adultes atteints d'un adénocarcinome gastrique ou de la jonction gastro-œsophagienne (JGO) H
Santé Canada approuve KEYTRUDA® comme traitement de première intention, en association avec une chimiothérapie à base de fluoropyrimidine et de platine, des adultes atteints d'un adénocarcinome gastrique ou de la jonction gastro-œsophagienne (JGO) HER2 négatif non résécable... More...>> |
| 04/19/2024 | 7:04AM | PRNCA | Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-conta
Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy Canada NewsWire KIRKLAND, QC, April 19, 2024... More...>> |
| 04/10/2024 | 7:13AM | IHMARKETNEWS | Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News
Delta Air Lines (NYSE:DAL) – Delta Airlines reported a first-quarter profit of $37 million, a significant increase compared to the $363 million loss from the previous year. With adjusted revenue of $12.56 billion, the company surpassed Wall Street expectations, attributing the success to strong demand for leisure... More...>> |
| 04/04/2024 | 6:45AM | BW | Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA for the first-line treatment of certain patients with metastatic non-small cell lung... More...>> |
| 04/03/2024 | 8:00AM | BW | REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the first patient has been dosed in the REJOICE-Ovarian01 phase 2/3 trial evaluating the efficacy and safety of investigational raludotatug deruxtecan (R-DXd) in patients with platinum-resistant... More...>> |
| 04/01/2024 | 6:45AM | BW | Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its first-quarter 2024 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, April 25. During the call, company executives will provide an overview of Merck’s performance for the quarter... More...>> |
| 03/28/2024 | 6:45AM | BW | European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results and represents the sixth approval for KEYTRUDA in lung cancer in Europe Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission... More...>> |
| 03/27/2024 | 6:54AM | IHMARKETNEWS | GameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News
GameStop (NYSE:GME) – GameStop reported $1.79 billion in revenue for the fourth quarter, which is less than the $2.23 billion earned in the same quarter of the previous year. However, the company announced an adjusted earnings per share of 22 cents, compared to the previous year’s 16 cents per share. Shares... More...>> |
| 03/26/2024 | 6:21PM | BW | FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
WINREVAIR is a breakthrough biologic for this rare, progressive disease WINREVAIR on top of background therapy significantly improved exercise capacity and multiple important secondary outcome measures compared to background therapy alone Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced... More...>> |
| 03/21/2024 | 6:45AM | BW | Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYLYNK-006 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with maintenance LYNPARZA, a PARP inhibitor, did not meet its dual primary endpoints of overall survival (OS) and progression-free... More...>> |
| 03/19/2024 | 9:00AM | BW | Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
Results from multiple Phase 3 trials of V116 and a real-world evidence study of pneumococcal serotypes presented at the 13th Meeting of the International Society of Pneumonia and Pneumococcal Diseases If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults Merck (NYSE: MRK... More...>> |
| 03/15/2024 | 4:23PM | PRNUS | FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform
FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform PR Newswire HOD HASHARON, Israel, March 15, 2024 Cutting edge & AI solution for continuous and precise monitoring of individual swine weight HOD HASHARON, Israel, March 15, 2024 /PRNewswire/ -- FarmSee, a pioneer in camera-based... More...>> |
| 03/15/2024 | 6:45AM | BW | Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
KEYTRUDA plus CRT is the first immunotherapy-based regimen to demonstrate a statistically significant improvement in OS in these patients Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating KEYTRUDA... More...>> |
| 03/13/2024 | 3:00AM | BW | Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today, at the EUROGIN 2024 HPV Congress, announced plans to initiate clinical development of a new investigational multi-valent HPV vaccine... More...>> |
| 03/11/2024 | 8:15AM | BW | Merck Completes Acquisition of Harpoon Therapeutics, Inc.
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics... More...>> |
| 03/06/2024 | 10:25AM | BW | Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
– Week 24 Results Support Continued Development as a Potential Long-Acting Oral Combination Treatment Option in Virologically Suppressed People with HIV – – Novel Investigational Combination Regimen has the Potential to be the First Oral Weekly HIV Treatment, Helping to Address Unmet Needs – Gilead Sciences, Inc... More...>> |
| 03/05/2024 | 9:03AM | IHMARKETNEWS | Futures Pointing To Continued Weakness On Wall Street
The major U.S. index futures are currently pointing to a lower open on Tuesday, with stocks likely to see further downside following the modest pullback seen on Monday. Traders may continue to cash in on recent strength in the markets, which lifted the S&P 500 and the Nasdaq to record closing highs last Friday. Uncertainty... More...>> |